SRNE - Sizing Up Sorrento Therapeutics. AGAIN
- Serial deal maker Sorrento Therapeutics, Inc. has amassed a significant pipeline of immuno-oncology, pain management, and Covid-19 assets.
- The plethora of programs combined with its communication almost exclusively through press release renders it challenging to determine the company’s priorities.
- With enthusiastic support from Street analysts, Sorrento merited a deeper dive.
- A full investment analysis and covered call recommendation follow in the paragraphs below.
For further details see:
Sizing Up Sorrento Therapeutics. AGAIN